[This page is intended to provide a study summary, the sections of which are below. Please complete these sections, as applicable. The headings below are suggested headings. You can remove inapplicable sections, or add new ones relevant to your study]
Investigator Names and Contact Information
Paul Brennan [ firstname.lastname@example.org] and Nicolas Schlecht [email@example.com]
Pilot data from the European Prospective Investigation into Nutrition and Cancer (EPIC) study indicate that circulating HPV16 E6 antibodies were present in a large proportion of oropharyngeal cancer (34.8% of 135 cases) up to 12 years before diagnosis, while the proportion was rare among controls (0.6% of 1599 controls). This result was noteworthy as it raises the possibility that HPV16 E6 antibodies can be used as a highly specific biomarker to predict oropharyngeal cancer many years prior to diagnosis. Lifetime risk or oropharyngeal cancer for those testing positive approached 50%. We propose to establish a head and neck cancer cohort consortium initiative in order to specifically evaluate the sensitivity, specificity, true latent period, and implications for those who test HPV16 positive. By bringing together as many cohorts as possible, we plan to identify over 2000 head and neck cancer cases, including over 300 oropharynx cancer cases, and comparable controls. We will investigate residual effects for other head and neck cancer sites, as well as possible additional effects for other HPV types. Where feasible, we will also collect tumor tissue to identify the correlation between serology and tumor DNA markers for HPV infection. Finally, we will establish the infrastructure for a head and neck cancer cohort consortium that will subsequently be available for additional molecular epidemiology studies.